Precision at the Genome Level: Strategic Evolution of the US Nucleic Acid Therapeutics Market
The landscape of American biopharmaceuticals is undergoing a structural transformation as nucleic acid therapeutics evolve from specialized genetic interventions into a dominant therapeutic class. In 2026, the US market stands as the global epicenter for this shift, driven by a maturing pipeline of RNA-based drugs and a robust infrastructure for personalized medicine. For B2B stakeholders—from … Read more